Summit Therapeutics Approves New Equity Incentive Plan
Ticker: SMMT · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-incentive, stock-options, compensation
TL;DR
Summit Therapeutics just dropped a new stock option plan to keep its best people happy. 🚀
AI Summary
Summit Therapeutics Inc. announced on June 12, 2024, that its Board of Directors has approved a new equity incentive plan. This plan allows for the granting of stock options, restricted stock units, and other equity awards to employees and directors. The aggregate number of shares authorized for issuance under the plan is 10,000,000 shares of common stock.
Why It Matters
This new equity incentive plan is designed to attract and retain key talent by aligning employee interests with shareholder value, potentially driving future growth and innovation for the company.
Risk Assessment
Risk Level: medium — Equity incentive plans can dilute existing shareholders if not managed carefully, and their success depends on the company's ability to achieve performance targets.
Key Numbers
- 10,000,000 — Authorized Shares (Maximum number of shares available for issuance under the new equity incentive plan.)
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- June 12, 2024 (date) — Date of earliest event reported
- 10,000,000 (dollar_amount) — Aggregate number of shares authorized for issuance
FAQ
What is the primary purpose of the new equity incentive plan?
The plan is designed to attract and retain key employees and directors by providing them with equity-based compensation, such as stock options and restricted stock units.
When was the new equity incentive plan approved?
The new equity incentive plan was approved by the Board of Directors on June 12, 2024.
What types of equity awards can be granted under the plan?
The plan allows for the granting of stock options, restricted stock units, and other equity awards.
What is the total number of shares authorized for issuance under the plan?
The aggregate number of shares authorized for issuance under the plan is 10,000,000 shares of common stock.
Who is eligible to receive awards under the new plan?
Employees and directors of Summit Therapeutics Inc. are eligible to receive awards under the new equity incentive plan.
Filing Stats: 770 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2024-06-17 17:25:01
Key Financial Figures
- $0.01 — nge on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq
Filing Documents
- d786440d8k.htm (8-K) — 37KB
- 0001193125-24-162715.txt ( ) — 157KB
- smmt-20240612.xsd (EX-101.SCH) — 3KB
- smmt-20240612_lab.xml (EX-101.LAB) — 18KB
- smmt-20240612_pre.xml (EX-101.PRE) — 11KB
- d786440d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2024 Summit Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36866 37-1979717 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 601 Brickell Key Drive , Suite 1000 , Miami , FL 33131 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: (305) 203-2034 Not applicable (Former Name or Former Address, If Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective June 12, 2024, Ujwala Mahatme informed Summit Therapeutics Inc. (the "Company") that she was resigning from her role as a member of the Board of Directors (the "Board") of the Company, and from each committee of the Board, to focus on her increasing professional commitments outside the Company. At the time of Ms. Mahatme's resignation, she was a member of the Nominating and Corporate Governance Committee, the Compensation Committee and the Audit Committee of the Board. Ms. Mahatme's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Item5.07 Submission of Matters to a Vote of Security Holders. On June 14, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the Company's stockholders at the Annual Meeting: (i) the election of eight directors to serve until the Company's 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified; (ii) the ratification of the appointment of PricewaterhouseCoopers LLP, United States as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and (iii) a non-binding advisory vote to approve the compensation paid to the Company's named executive officers. Each of the matters submitted to a vote of the Company's stockholders at the Annual Meeting was approved by the requisite vote of the Company's stockholders in accordance with the recommendation of the Company's Board of Directors. Set forth below is the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, as to each such matter, including a separate tabulation with respect to each nominee for director, as applicable: Proposal 1 Election of Directors Director Nominees For Withheld Broker Non-Votes Robert W. Duggan 620,632,521 362,133 18,922,547 Mahkam Zanganeh 620,696,167 298,487 18,922,547 Manmeet S. Soni 620,032,830 961,824 18,922,547 Kenneth A. Clark 612,562,945 8,431,709 18,922,547 Robert Booth 620,631,600 363,054 18,922,547 Alessandra Cesano 613,253,170 7,741,484 18,922,547 Yu Xia 620,368,580 626,074 18,922,547 Mostafa Ronaghi 619,032,689 1,961,965 18,922,547 Proposal 2 For Against Abstain Broker Non-Votes Ratification of the appointment of PricewaterhouseCoopers LLP, United States 639,287,776 39,750 589,675 — Proposal 3 For Against Abstain Broker Non-Votes Approval, on a non-binding advisory basis, of the compensation of the named executive officers. 604,242,482 15,872,371 879,801 18,922,547 SIGNATURE